<p>加拿大市場表現出韌性，最近多倫多證券交易所（TSX）上漲超過 2%，儘管全球市場面臨關税不確定性和經濟壓力。在這樣的環境下，投資者往往會超越大型指數，尋找在小型股票等較不知名領域的機會。儘管 “便士股票” 這個術語可能顯得過時，但這些較小或較新的公司在強大的財務支持和穩健的基本面下，仍然可以提供顯著的增長潛力。</p>
<h3>加拿大十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Westbridge Renewable Energy (TSXV:WEB)</td>
<td>CA$0.61</td>
<td>CA$6170 萬</td>
<td>✅ 4 ⚠️ 4 查看分析</td>
</tr>
<tr>
<td>NTG Clarity Networks (TSXV:NCI)</td>
<td>CA$1.69</td>
<td>CA$6998 萬</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Orezone Gold (TSX:ORE)</td>
<td>CA$1.31</td>
<td>CA$68519 萬</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Dynacor Group (TSX:DNG)</td>
<td>CA$4.70</td>
<td>CA$19839 萬</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Amerigo Resources (TSX:ARG)</td>
<td>CA$1.69</td>
<td>CA$2.824 億</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>PetroTal (TSX:TAL)</td>
<td>CA$0.57</td>
<td>CA$5.2169 億</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>McCoy Global (TSX:MCB)</td>
<td>CA$2.66</td>
<td>CA$7094 萬</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Findev (TSXV:FDI)</td>
<td>CA$0.48</td>
<td>CA$1318 萬</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>BluMetric Environmental (TSXV:BLM)</td>
<td>CA$1.21</td>
<td>CA$4357 萬</td>
<td>✅ 2 ⚠️ 4 查看分析</td>
</tr>
<tr>
<td>Enterprise Group (TSX:E)</td>
<td>CA$1.26</td>
<td>CA$9846 萬</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們 TSX 便士股票篩選器的 930 只股票的完整列表。</p>
<p>下面我們展示了一些經過篩選的股票。</p>
<h2>Calfrac Well Services (TSX:CFW)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Calfrac Well Services Ltd.及其子公司在加拿大、美國和阿根廷提供專業的油田服務，市值為 CA$2.9288 億。</p>
<p><strong>運營：</strong> 該公司主要通過油井設備和服務產生收入，金額為 CA$15.7 億。</p>
<p><strong>市值：</strong> CA$2.9288 億</p>
<p>Calfrac Well Services 的市值為 CA$2.9288 億，最近報告了 2024 年第四季度的淨虧損，銷售額下降。過去五年，該公司的債務顯著減少，但其當前的淨債務與股本比率仍高達 42.4%。雖然短期和長期負債由資產覆蓋，但利息支付未能得到盈利的良好覆蓋。最近的高管變動可能會影響未來的戰略和運營。儘管去年盈利增長為負，Calfrac 預計在競爭激烈的能源服務行業中，未來的利潤將適度增長 4.61%。</p>
<ul>
<li>點擊這裏瞭解 Calfrac Well Services 的細微差別，查看我們的詳細財務健康報告。</li>
<li>查看我們的增長表現報告，以獲取對 Calfrac Well Services 未來的洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e9eb34c4-7b23-4bc4-a84f-cbb170d0732b/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e9eb34c4-7b23-4bc4-a84f-cbb170d0732b/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 4 月的 TSX:CFW 收入與支出細分</p>
<h2>Eupraxia Pharmaceuticals (TSX:EPRX)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Eupraxia Pharmaceuticals Inc.是一家臨牀階段的生物技術公司，專注於發現、開發和營銷生物技術領域的技術，市值為 CA$1.5917 億。</p>
<p><strong>運營：</strong> Eupraxia Pharmaceuticals Inc.尚未報告任何具體的收入細分。</p>
<p><strong>市值：</strong> CA$1.5917 億</p>
<p>Eupraxia Pharmaceuticals Inc.的市值為 CA$1.5917 億，仍處於無收入狀態，專注於 EP-104GI 和 EP-104IAR 等創新治療的臨牀試驗。儘管處於虧損狀態，該公司報告 2024 年的淨虧損減少至 2550 萬美元，較去年有所改善。Eupraxia 無債務，短期資產顯著超過負債，現金流可持續超過一年。最近的高管變動包括任命 Alex Rothwell 為首席財務官，考慮到他在資本市場的豐富經驗，可能會增強財務戰略。管理團隊的平均任期為 2.4 年，表明在持續開發努力中具有適度的經驗水平。</p>
<ul>
<li>點擊這裏閲讀我們的資產負債表健康報告，深入瞭解 Eupraxia Pharmaceuticals 的表現。</li>
<li>通過我們的詳細增長報告評估 Eupraxia Pharmaceuticals 未來的收益預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/41b98a10-956b-4e43-8e6b-7e5eb5a9c99c/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/41b98a10-956b-4e43-8e6b-7e5eb5a9c99c/chart/financial-position-analysis"/></p>
<p>截至 2025 年 4 月的 TSX:EPRX 財務狀況分析</p>
<h2>Amex Exploration (TSXV:AMX)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Amex Exploration Inc.及其子公司專注於在加拿大探索黃金礦產，市值為 CA$1.0882 億。</p>
<p><strong>運營：</strong> Amex Exploration Inc.未報告任何具體的收入細分，主要專注於在加拿大的黃金礦產探索。</p>
<p><strong>市值：</strong> CA$1.0882 億</p>
<p>Amex Exploration Inc.的市值為 CA$1.0882 億，處於無收入狀態，專注於黃金探索。該公司最近實現了盈利，儘管其股本回報率仍然較低，為 1.1%。Amex 的戰略擴張包括收購 Perron West 項目，顯著增加了其在魁北克和安大略省的土地持有和探索潛力。最近來自 Perron 項目的鑽探結果顯示出中央多金屬區的礦化延伸前景。儘管短期資產超過負債，但長期負債未能完全由當前資產覆蓋。Amex 無債務，管理團隊經驗豐富，繼續追求積極的探索戰略，以增強資源潛力。</p>
<ul>
<li>點擊這裏深入瞭解 Amex Exploration 的具體情況，查看我們的資產負債表健康報告。</li>
<li>通過訪問我們的收益增長報告評估 Amex Exploration 的前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cf193b4c-6b63-4bf7-a329-87e698dec26a/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cf193b4c-6b63-4bf7-a329-87e698dec26a/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 4 月的 TSXV:AMX 債務與股本歷史及分析</p>
<h2>抓住機會</h2>
<ul>
<li>點擊此鏈接訪問 930 只 TSX 便士股票的完整列表。</li>
<li>尋找替代機會？我們發現 25 只預計明年將支付超過 6% 股息收益率的美國股票。免費查看完整列表。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>如果您想交易 Eupraxia Pharmaceuticals，請在專業人士信賴的最低成本平台 Interactive Brokers 開設賬户。</p>
<p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓您可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
<p>享受無隱藏費用，無賬户最低要求，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的費用。</p>
<p>贊助內容</p>

EPRX

<p>多倫多證券交易所（TSX）上漲超過 2%，促使投資者探索低價股以尋找增長機會。值得注意的公司包括 Calfrac Well Services，該公司在 2024 年第四季度報告了淨虧損，但預計利潤將適度增長。Eupraxia Pharmaceuticals 仍處於無收入狀態，但沒有債務，現金流狀況良好。Amex Exploration 專注於黃金開採，儘管股本回報率較低，但最近實現了盈利。這些公司突顯了在更廣泛市場不確定性中，鮮為人知的股票所藴含的潛力</p>

<p>The Canadian market has shown resilience, with the TSX rising over 2% recently, even as global markets grapple with tariff uncertainties and economic pressures. In such a climate, investors often look beyond the larger indices to find opportunities in lesser-known areas like penny stocks. Although the term &#34;penny stocks&#34; might seem outdated, these smaller or newer companies can offer significant potential for growth when backed by strong financials and sound fundamentals.</p>
<div class="lb-trans"><p>加拿大市場表現出韌性，最近多倫多證券交易所（TSX）上漲超過 2%，儘管全球市場面臨關税不確定性和經濟壓力。在這樣的環境下，投資者往往會超越大型指數，尋找在小型股票等較不知名領域的機會。儘管 “便士股票” 這個術語可能顯得過時，但這些較小或較新的公司在強大的財務支持和穩健的基本面下，仍然可以提供顯著的增長潛力。</p>
</div><h3>Top 10 Penny Stocks In Canada</h3>
<div class="lb-trans"><h3>加拿大十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Westbridge Renewable Energy (TSXV:WEB)</td>
<td>CA$0.61</td>
<td>CA$61.7M</td>
<td>✅ 4 ⚠️ 4 View Analysis &gt;</td>
</tr>
<tr>
<td>NTG Clarity Networks (TSXV:NCI)</td>
<td>CA$1.69</td>
<td>CA$69.98M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Orezone Gold (TSX:ORE)</td>
<td>CA$1.31</td>
<td>CA$685.19M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Dynacor Group (TSX:DNG)</td>
<td>CA$4.70</td>
<td>CA$198.39M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Amerigo Resources (TSX:ARG)</td>
<td>CA$1.69</td>
<td>CA$282.4M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>PetroTal (TSX:TAL)</td>
<td>CA$0.57</td>
<td>CA$521.69M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>McCoy Global (TSX:MCB)</td>
<td>CA$2.66</td>
<td>CA$70.94M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Findev (TSXV:FDI)</td>
<td>CA$0.48</td>
<td>CA$13.18M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>BluMetric Environmental (TSXV:BLM)</td>
<td>CA$1.21</td>
<td>CA$43.57M</td>
<td>✅ 2 ⚠️ 4 View Analysis &gt;</td>
</tr>
<tr>
<td>Enterprise Group (TSX:E)</td>
<td>CA$1.26</td>
<td>CA$98.46M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Westbridge Renewable Energy (TSXV:WEB)</td>
<td>CA$0.61</td>
<td>CA$6170 萬</td>
<td>✅ 4 ⚠️ 4 查看分析</td>
</tr>
<tr>
<td>NTG Clarity Networks (TSXV:NCI)</td>
<td>CA$1.69</td>
<td>CA$6998 萬</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Orezone Gold (TSX:ORE)</td>
<td>CA$1.31</td>
<td>CA$68519 萬</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Dynacor Group (TSX:DNG)</td>
<td>CA$4.70</td>
<td>CA$19839 萬</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Amerigo Resources (TSX:ARG)</td>
<td>CA$1.69</td>
<td>CA$2.824 億</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>PetroTal (TSX:TAL)</td>
<td>CA$0.57</td>
<td>CA$5.2169 億</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>McCoy Global (TSX:MCB)</td>
<td>CA$2.66</td>
<td>CA$7094 萬</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Findev (TSXV:FDI)</td>
<td>CA$0.48</td>
<td>CA$1318 萬</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>BluMetric Environmental (TSXV:BLM)</td>
<td>CA$1.21</td>
<td>CA$4357 萬</td>
<td>✅ 2 ⚠️ 4 查看分析</td>
</tr>
<tr>
<td>Enterprise Group (TSX:E)</td>
<td>CA$1.26</td>
<td>CA$9846 萬</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 930 stocks from our TSX Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們 TSX 便士股票篩選器的 930 只股票的完整列表。</p>
</div><p>Underneath we present a selection of stocks filtered out by our screen.</p>
<div class="lb-trans"><p>下面我們展示了一些經過篩選的股票。</p>
</div><h2>Calfrac Well Services (TSX:CFW)</h2>
<div class="lb-trans"><h2>Calfrac Well Services (TSX:CFW)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Calfrac Well Services Ltd., along with its subsidiaries, offers specialized oilfield services in Canada, the United States, and Argentina, and has a market cap of CA$292.88 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Calfrac Well Services Ltd.及其子公司在加拿大、美國和阿根廷提供專業的油田服務，市值為 CA$2.9288 億。</p>
</div><p><strong>Operations:</strong> The company generates its revenue primarily from oil well equipment and services, amounting to CA$1.57 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過油井設備和服務產生收入，金額為 CA$15.7 億。</p>
</div><p><strong>Market Cap:</strong> CA$292.88M</p>
<div class="lb-trans"><p><strong>市值：</strong> CA$2.9288 億</p>
</div><p>Calfrac Well Services, with a market cap of CA$292.88 million, recently reported a net loss for Q4 2024 amid declining sales. The company has seen significant debt reduction over the past five years, yet its current net debt to equity ratio remains high at 42.4%. While short-term and long-term liabilities are covered by assets, interest payments are not well covered by earnings. Recent executive changes could impact future strategy and operations. Despite negative earnings growth last year, Calfrac is forecasted to grow profits modestly at 4.61% annually moving forward in the competitive energy services sector.</p>
<div class="lb-trans"><p>Calfrac Well Services 的市值為 CA$2.9288 億，最近報告了 2024 年第四季度的淨虧損，銷售額下降。過去五年，該公司的債務顯著減少，但其當前的淨債務與股本比率仍高達 42.4%。雖然短期和長期負債由資產覆蓋，但利息支付未能得到盈利的良好覆蓋。最近的高管變動可能會影響未來的戰略和運營。儘管去年盈利增長為負，Calfrac 預計在競爭激烈的能源服務行業中，未來的利潤將適度增長 4.61%。</p>
</div><ul>
<li>Click here to discover the nuances of Calfrac Well Services with our detailed analytical financial health report.</li>
<li>Review our growth performance report to gain insights into Calfrac Well Services' future.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解 Calfrac Well Services 的細微差別，查看我們的詳細財務健康報告。</li>
<li>查看我們的增長表現報告，以獲取對 Calfrac Well Services 未來的洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e9eb34c4-7b23-4bc4-a84f-cbb170d0732b/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/e9eb34c4-7b23-4bc4-a84f-cbb170d0732b/chart/revenue-and-expenses-breakdown"/></p>
<p>TSX:CFW Revenue &amp; Expenses Breakdown as at Apr 2025</p>
<div class="lb-trans"><p>截至 2025 年 4 月的 TSX:CFW 收入與支出細分</p>
</div><h2>Eupraxia Pharmaceuticals (TSX:EPRX)</h2>
<div class="lb-trans"><h2>Eupraxia Pharmaceuticals (TSX:EPRX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Eupraxia Pharmaceuticals Inc. is a clinical stage biotechnology company focused on discovering, developing, and marketing technologies in the biotechnology sector, with a market cap of CA$159.17 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Eupraxia Pharmaceuticals Inc.是一家臨牀階段的生物技術公司，專注於發現、開發和營銷生物技術領域的技術，市值為 CA$1.5917 億。</p>
</div><p><strong>Operations:</strong> Eupraxia Pharmaceuticals Inc. has not reported any specific revenue segments.</p>
<div class="lb-trans"><p><strong>運營：</strong> Eupraxia Pharmaceuticals Inc.尚未報告任何具體的收入細分。</p>
</div><p><strong>Market Cap:</strong> CA$159.17M</p>
<div class="lb-trans"><p><strong>市值：</strong> CA$1.5917 億</p>
</div><p>Eupraxia Pharmaceuticals Inc., with a market cap of CA$159.17 million, remains pre-revenue as it focuses on clinical trials for innovative treatments like EP-104GI and EP-104IAR. Despite its unprofitable status, the company reported a reduced net loss of US$25.5 million for 2024 compared to the previous year. Eupraxia is debt-free, with short-term assets significantly exceeding liabilities and a cash runway extending over a year. Recent executive changes include appointing Alex Rothwell as CFO, potentially enhancing financial strategy given his extensive capital markets experience. The management team has an average tenure of 2.4 years, indicating moderate experience levels amidst ongoing development efforts.</p>
<div class="lb-trans"><p>Eupraxia Pharmaceuticals Inc.的市值為 CA$1.5917 億，仍處於無收入狀態，專注於 EP-104GI 和 EP-104IAR 等創新治療的臨牀試驗。儘管處於虧損狀態，該公司報告 2024 年的淨虧損減少至 2550 萬美元，較去年有所改善。Eupraxia 無債務，短期資產顯著超過負債，現金流可持續超過一年。最近的高管變動包括任命 Alex Rothwell 為首席財務官，考慮到他在資本市場的豐富經驗，可能會增強財務戰略。管理團隊的平均任期為 2.4 年，表明在持續開發努力中具有適度的經驗水平。</p>
</div><ul>
<li>Get an in-depth perspective on Eupraxia Pharmaceuticals' performance by reading our balance sheet health report here.</li>
<li>Assess Eupraxia Pharmaceuticals' future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏閲讀我們的資產負債表健康報告，深入瞭解 Eupraxia Pharmaceuticals 的表現。</li>
<li>通過我們的詳細增長報告評估 Eupraxia Pharmaceuticals 未來的收益預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/41b98a10-956b-4e43-8e6b-7e5eb5a9c99c/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/41b98a10-956b-4e43-8e6b-7e5eb5a9c99c/chart/financial-position-analysis"/></p>
<p>TSX:EPRX Financial Position Analysis as at Apr 2025</p>
<div class="lb-trans"><p>截至 2025 年 4 月的 TSX:EPRX 財務狀況分析</p>
</div><h2>Amex Exploration (TSXV:AMX)</h2>
<div class="lb-trans"><h2>Amex Exploration (TSXV:AMX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Amex Exploration Inc., along with its subsidiaries, focuses on exploring gold mining properties in Canada and has a market capitalization of CA$108.82 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Amex Exploration Inc.及其子公司專注於在加拿大探索黃金礦產，市值為 CA$1.0882 億。</p>
</div><p><strong>Operations:</strong> Amex Exploration Inc. does not report any specific revenue segments, as it is primarily focused on the exploration of gold mining properties in Canada.</p>
<div class="lb-trans"><p><strong>運營：</strong> Amex Exploration Inc.未報告任何具體的收入細分，主要專注於在加拿大的黃金礦產探索。</p>
</div><p><strong>Market Cap:</strong> CA$108.82M</p>
<div class="lb-trans"><p><strong>市值：</strong> CA$1.0882 億</p>
</div><p>Amex Exploration Inc., with a market cap of CA$108.82 million, is pre-revenue, focusing on gold exploration. The company has achieved profitability recently, though its Return on Equity remains low at 1.1%. Amex's strategic expansion includes acquiring the Perron West Project, significantly increasing its land holdings and exploration potential in Quebec and Ontario. Recent drill results from the Perron Project indicate promising mineralization extensions in the Central Polymetallic Zone. Despite short-term assets exceeding liabilities, long-term liabilities are not fully covered by current assets. With no debt and a seasoned management team, Amex continues to pursue aggressive exploration strategies to enhance resource potential.</p>
<div class="lb-trans"><p>Amex Exploration Inc.的市值為 CA$1.0882 億，處於無收入狀態，專注於黃金探索。該公司最近實現了盈利，儘管其股本回報率仍然較低，為 1.1%。Amex 的戰略擴張包括收購 Perron West 項目，顯著增加了其在魁北克和安大略省的土地持有和探索潛力。最近來自 Perron 項目的鑽探結果顯示出中央多金屬區的礦化延伸前景。儘管短期資產超過負債，但長期負債未能完全由當前資產覆蓋。Amex 無債務，管理團隊經驗豐富，繼續追求積極的探索戰略，以增強資源潛力。</p>
</div><ul>
<li>Dive into the specifics of Amex Exploration here with our thorough balance sheet health report.</li>
<li>Evaluate Amex Exploration's prospects by accessing our earnings growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Amex Exploration 的具體情況，查看我們的資產負債表健康報告。</li>
<li>通過訪問我們的收益增長報告評估 Amex Exploration 的前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cf193b4c-6b63-4bf7-a329-87e698dec26a/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/cf193b4c-6b63-4bf7-a329-87e698dec26a/chart/debt-equity-history-analysis"/></p>
<p>TSXV:AMX Debt to Equity History and Analysis as at Apr 2025</p>
<div class="lb-trans"><p>截至 2025 年 4 月的 TSXV:AMX 債務與股本歷史及分析</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Access the full spectrum of 930 TSX Penny Stocks by clicking on this link.</li>
<li>Looking For Alternative Opportunities? We've found 25 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接訪問 930 只 TSX 便士股票的完整列表。</li>
<li>尋找替代機會？我們發現 25 只預計明年將支付超過 6% 股息收益率的美國股票。免費查看完整列表。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>If you're looking to trade Eupraxia Pharmaceuticals, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果您想交易 Eupraxia Pharmaceuticals，請在專業人士信賴的最低成本平台 Interactive Brokers 開設賬户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓您可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受無隱藏費用，無賬户最低要求，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的費用。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>贊助內容</p>
</div>

TSX 便士股亮點：Calfrac Well Services 及另外兩個引人注目的選擇